Cipher Pharmaceuticals (CPH) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue rose 71% year-over-year to $10.4 million, driven by the Natroba acquisition and strong Epuris growth.

• Product revenue surged 213% in Q3 to $9.3 million, while licensing revenue fell 66% due to lower Absorica royalties.

• Net income for the nine months ended Q3 2024 was $8.2 million, down from $12.7 million year-over-year, impacted by acquisition costs and lower licensing revenue.

• Transitioning sales from a prior co-promotion partner, impacting Q3 sales and earnings, with normalization expected in 2025.

• Strengthened management with new appointments, including Chief Business Officer, to drive business development and M&A.

Financial highlights

• Gross margin on product revenue improved to 79% in Q3 2024 from 64% in Q3 2023, reflecting the higher-margin Natroba business.

• Adjusted EBITDA for Q3 was $4.1 million, up 13% year-over-year; year-to-date Adjusted EBITDA rose 9% to $10.7 million.

• EBITDA for the nine months decreased 14% to $7.4 million, reflecting transaction costs and amortization.

• Ended Q3 with $9.5 million in cash after funding the Natroba acquisition.

• Total assets increased to $153.9 million as of September 30, 2024, from $86.0 million at year-end 2023.

Outlook and guidance

• Expect transition from co-promotion partner to complete by end of 2024, with improved sales and earnings in 2025.

• Evaluating commercial strategy for Natroba in Canada, with regulatory steps planned for Q1 2025.

• Two to three advanced-stage acquisition/licensing opportunities under review, with potential execution in 2025.

• Focus on integrating Natroba, expanding its U.S. market share, and out-licensing globally.

• Collaboration with Moberg Pharma on MOB-015 Phase III trial, with results expected by January 2025.